PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

C12N 15/12, C07K 14/47, A61K 38/17

A3

(11) International Publication Number:

WO 98/42741

(43) International Publication Date:

1 October 1998 (01.10.98)

(21) International Application Number:

PCT/US98/05972

(22) International Filing Date:

25 March 1998 (25.03.98)

(30) Priority Data:

08/825,145 09/046,881 25 March 1997 (25.03.97) US

24 March 1998 (24.03.98) US

- (71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 CambridgePark Drive, Cambridge, MA 02140 (US).
- (72) Inventors: JACOBS, Kenneth; 151 Beaumont Street, Newton, MA 02160 (US). MCCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US). LAVALLIE, Edward, R.; 113 Ann Lee Road, Harvard, MA 01451 (US). RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US). MERBERG, David; 2 Orchard Street, Acton, MA 01720 (US). TREACY, Maurice; 93 Walcott Road, Chestnut Hill, MA 02167 (US). SPAULDING, Vikki; 11 Meadowbank Road, Billerica, MA 01821 (US). AGOSTINO, Michael, J.; 26 Wolcott Avenue, Andover, MA 01810 (US).
- (74) Agent: SPRUNGER, Suzanne, A.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM. GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(88) Date of publication of the international search report:

23 December 1998 (23.12.98)

- (57) Abstract

Polynucleotides and the proteins encoded thereby are disclosed.

(54) Title: SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	$\mathbf{L}\mathbf{V}$	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	ТJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	$\mathbf{z}\mathbf{w}$	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	\mathbf{PL}	Poland		
CN	China	KR	Republic of Korea	PТ	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
\mathbf{EE}	Estonia	LR	Liberia	SG	Singapore		

International Application No PCT/US 98/05972

a. classification of subject matter IPC 6 C12N15/12 C07K14/47 A61K38/17 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) C12N C07K A61K IPC 6 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category ' 1-13 FILIPEK A. AND WOJDA U.: "p30, a novel γ protein target of mouse calcyclin (S100A6)" BIOCHEMICAL JOURNAL. vol. 320, no. 2, 1 December 1996, pages 585-587, XP002069354 see page 587, left-hand column, paragraph 1,13 Database EMBL, entry HSAA47377, X Accession number AA147377 14 December 1996 99% identity with Seq.ID:1 nt.5-348 XP002069355 cited in the application 1-13 Υ see the whole document -/--Patent family members are listed in annex. Further documents are listed in the continuation of box C. X Χ Special categories of cited documents : "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date involve an inventive step when the document is taken alone "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another "Y" document of particular relevance; the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled other means in the art. *P* document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 2 8, 09, 98 26 June 1998 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Macchia, G

International Application No
PCT/US 98/05972

C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database EMBL, entry HSAA29803, Accession number AA129803 6 December 1996 99% identity with Seq.ID:1 nt.202-603 XP002069356	1,13
Υ	see the whole document	1-13
X	Database EMBL, entry HSAA47341, Accession number AA147341 14 December 1996 97% identity with Seq.ID:1 nt.509-937 reverse orientation XP002069357 see the whole document	1,13
X	Database EMBL, entry HSAA28382, Accession number AA128382 6 December 1996 99% identity with Seq.ID:1 nt.614-1045 reverse orientation XP002069358 see the whole document	1,13
X	Database EMBL, entry HSAA59926, Accession number AA159926 19 January 1997 99% identity with Seq.ID:1 nt.973-1459 reverse orientation XP002069359 see the whole document	1,13
X .	EP 0 679 716 A (MATSUBARA KENICHI; OKUBO KOUSAKU (JP)) 2 November 1995 see abstract see page 5, line 34 - page 9, line 45 see page 195; table 175 Seq.ID:6271 is 100% homologous to Seq.ID1 nt.609-891 see page 1783 - page 1784	1,13
Α	WO 97 07198 A (GENETICS INSTITUTE INC.) 27 February 1997	
А	US 5 536 637 A (JACOBS KENNETH) 16 July 1996 cited in the application	

Intrational application No.

PCT/US 98/05972

Box I	Observations where certain claims were found unsearchable (Continuation of Item 1 of Ilirst sneet)
This Inter	national Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
. —	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claim 12 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
<u> </u>	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
	rnational Searching Authority found multiple inventions in this international application, as follows: Further information.sheet
	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-13
Remark	on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-13

Polynucleotide comprising the nucleotide sequence of Seq.ID:1 and encoding a polypeptide of Seq.ID:2 or fragments. Polynucleotide fragments, variants, homologues, gene thereof. Host cell transformed with said polynucleotide. Protein comprising an amino acid sequence of Seq.ID:2 or fragments thereof. Process for producing said protein. Application of said protein in therapy.

2. Claims: 14-16

Polynucleotide comprising the nucleotide sequence of Seq.ID:3 and encoding a polypeptide of Seq.ID:4 or fragments. Polynucleotide fragments, variants, homologues, gene thereof. Protein comprising an amino acid sequence of Seq.ID:4 or fragments thereof.

3. Claims: 17-19

As invention 2 but concerning Seq.ID:5 and 6.

4. Claims: 20-22

As invention 2 but concerning Seq.ID:7 and 8.

5. Claims: 23-25

As invention 2 but concerning Seq.ID:9, 10 and 11.

6. Claims: 26-28

As invention 2 but concerning Seq.ID:12 and 13.

7. Claims: 29-31

As invention 2 but concerning Seq.ID:14 and 15.

8. Claims: 32-34

As invention 2 but concerning Seq.ID:16, 17, 18 and 19.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

9. Claims: 35-37

As invention 2 but concerning Seq.ID:20 and 21.

10. Claims: 38-40

As invention 2 but concerning Seq.ID:22 and 23.

In lation on patent family members

International Application No
PCT/US 98/05972

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0679716 A	02-11-95	AU 8116494 A CA 2153480 A WO 9514772 A	13-06-95 01-06-95 01-06-95
WO 9707198 A	27-02-97	US 5707829 A AU 6712396 A AU 6768596 A EP 0839196 A EP 0851875 A WO 9704097 A	13-01-98 18-02-97 12-03-97 06-05-98 08-07-98 06-02-97
US 5536637 A	16-07-96	US 5712116 A	27-01-98